CArdioversion of Short Duration Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

32 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is aimed at testing the hypothesis whether atrial fibrillary rate (AFR), as a measure of atrial electrical remodeling assessed from surface ECG, is predictive of sinus rhythm maintenance after electrical cardioversion.

Earlier studies performed in a retrospective fashion suggested that high AFR exceeding 350-360 fibrillations per minute is an independent predictor of AF relapse after cardioversion, particularly in patients with duration of AF episode not exceeding 30 days, however this hypothesis has not been tested in a prospective study.

CASAF is an observational study that will enroll patients with short duration (\< 30 days) AF admitted for electrical cardioversion. Admission ECG will be extracted in a digital format and processed off-line for estimation of AFR. AF relapse will be assessed during 6-weeks long follow-up period during which ECG control will be scheduled at week 1 and 6.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Left Atrial Strain Values as an Early Predictor of Atrial Fibrillation

NCT06417112

Atrial Fibrillation Hypertension

COMPLETED

Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)

NCT01233648

Atrial Fibrillation

COMPLETED PHASE4

Atrial Fibrillation Prior and Post Elective Cardioversion

NCT05926401

Atrial Fibrillation

RECRUITING

Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men

NCT06200311

Fibrillation, Atrial Atrial Cardiomyopathy

RECRUITING NA

Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study

NCT02074566

Atrial Fibrillation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Electrocardiography Electrical Remodeling

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Recurrent AF verified by at least one ECG recording prior to the index admission
* Known onset of symptoms within 30 days from index admission.
* Sinus rhythm ECG within 30 days prior to the index admission If onset of symptoms is unknown.
* If duration of the present AF episode \>48 hours then thromboembolic risk should be minimized by either verifying that the patient is adequately anticoagulated according to the hospital routine or TEE performed to verify the lack of contraindications for electrical cardioversion.
* Echocardiography at any time since first onset of AF to verify the lack of significant valvular disease.
* Age older than 18 years.

Exclusion Criteria

* AF due to reversible cause or significant valvular heart disease
* Treatment with class I or III antiarrhythmic drugs within five half-lives of their elimination period. No amiodarone treatment within six months before admission
* Prior ablation of AF
* Unability to verify onset of symptoms within 30 days prior to the index admission

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No